Urology News and Research

Latest Urology News and Research

Celldex second quarter net loss increases to $10.2 million

Celldex Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2011. Celldex reported a net loss of $10.2 million, or $0.27 per share, for the second quarter of 2011 compared to a net loss of $9.5 million, or $0.30 per share, for the second quarter of 2010.

3 Aug 2011

British scientists find seven new gene variants linked to prostate cancer

Cancer Research UK-funded scientists have taken a further step to identifying men at a greater risk of prostate cancer with the discovery of seven new variants in the human genome that increase the chances of developing the disease. The research is published in Nature Genetics.

3 Aug 2011

A guide to safe and informed recovery after prostate cancer

Prostate cancer is the number two killer of American men, second only to lung cancer. It is a disease that affects more than 2 million American men, and in 2010 there were over 218,000 new diagnoses.

2 Aug 2011

Kenya Medical Services Minister to establish African Cancer Foundation

When Anyang' Nyong'o, Medical Services Minister of Kenya, returned cancer-free to his native land in March of this year, he made a commitment to the people of Kenya. "My experience is a wake-up call for us in Kenya," he proclaimed.

1 Aug 2011

Routine dipstick urine test may identify individuals with silent kidney disease

A simple and inexpensive urine test routinely done in family doctors' offices may be the key to identifying individuals who are silently undergoing rapid kidney function decline, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

29 Jul 2011

Celgene reports second quarter total revenue of $1.18 billion

Celgene Corporation announced non-GAAP net income of $417 million, or non-GAAP diluted earnings per share of $0.89, for the quarter ended June 30, 2011. Non-GAAP net income for the second quarter of 2010 was $323 million, or non-GAAP diluted earnings per share of $0.69.

28 Jul 2011

Watson to acquire portfolio of divested generic pharmaceutical products

Watson Pharmaceuticals, Inc. today announced a definitive agreement to acquire a portfolio of generic pharmaceutical products that are being divested as a result of the merger between Perrigo Company and Paddock Laboratories.

28 Jul 2011

Safeguard Scientifics reports consolidated net income of $121.8M for second quarter 2011

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced results of operations for the second quarter of 2011.

27 Jul 2011

Invaron, Columbia Laboratories enter license agreement for STRIANT buccal system

Columbia Laboratories, Inc. has entered into a license agreement with Invaron Pharmaceuticals Inc., a privately-held Canadian pharmaceutical company, for STRIANT in Canada.

27 Jul 2011

FDA clears ArthroCare's SpeedFix Suture System

ArthroCare Corp., a leader in developing state-of-the-art, minimally invasive surgical products, has announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its SpeedFix Suture System.

27 Jul 2011

Watson second quarter net revenue increases 24% to $1.1 billion

Watson Pharmaceuticals, Inc. today reported net revenue of $1.1 billion for the second quarter ended June 30, 2011, an increase of 24 percent when compared to $875.3 million in the second quarter 2010.

26 Jul 2011

GlaxoSmithKline files suit against Watson over generic JALYN

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market dutasteride and tamsulosin hydrochloride capsules.

25 Jul 2011

Janssen receives FDA Complete Response letter for SIMPONI sBLA to treat RA

Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter for its supplemental Biologics License Application (sBLA) for SIMPONI.

25 Jul 2011

C-sections on the rise: One in three mothers opting for procedure

According to the latest study reports, one in three births in the U.S. are now delivered by Caesarean section, which is an all time high and an increasd of 25 percent over seven years.

24 Jul 2011

U.S. News ranks Ronald Reagan UCLA Medical Center among top five American hospitals

Ronald Reagan UCLA Medical Center ranks among the top five American hospitals, according to a U.S. News & World Report survey that reviewed patient-outcomes data, reputation among physicians and other care-related factors. The medical center also was rated the best hospital in the western United States for the 22nd consecutive year and the No. 1 hospital in the Los Angeles metropolitan area.

22 Jul 2011

Taiho announces results of TAS-102 Phase II trial for metastatic colorectal cancer

Taiho Pharmaceutical Co., Ltd. announced on July 22 the results of a randomized, Phase II clinical trial for the novel oral nucleoside antitumor agent TAS-102 under development by the company for metastatic colorectal cancer, at the 9th Annual Meeting of the Japanese Society of Medical Oncology held in Yokohama.

22 Jul 2011

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

Janssen Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced today that the Gastrointestinal Drugs Advisory Committee of the U.S. Food and Drug Administration recommended the approval of REMICADE for the treatment of moderately to severely active ulcerative colitis in pediatric patients who have had an inadequate response to conventional therapy.

22 Jul 2011